This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

NCT02772601 PHASE1 COMPLETED

To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.

Details

Lead sponsor	AbbVie
Phase	PHASE1
Status	COMPLETED
Enrolment	21
Start date	Thu Sep 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 22 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Psoriasis

Interventions

• Caffeine
• Warfarin
• Omeprazole
• Metoprolol
• Midazolam
• Risankizumab

Countries

Germany